INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Article

Nanoparticles In Pharmaceutical Applications: Current Trends And Future Prospects

Aryan Minekar*, Seema Shinde, Nilesh Chougule

Department of Pharmaceutics, Ashokrao Mane Institute of Pharmacy, Ambap-416112, India

ARTICLE INFO
Published: 16 Oct 2024
Keywords:
Nanoparticle, Pharmaceutical, Future
DOI:
10.5281/zenodo.13941743

ABSTRACT

Nanoparticle-based drug delivery systems have emerged as a transformative approach in modern therapeutics, offering enhanced precision and efficacy in drug administration. This review article explores the current trends, innovations, challenges, and future prospects of nanoparticle technology in pharmaceutical applications. Recent advancements include the development of personalized nanomedicine, smart nanoparticles that respond to environmental stimuli, and theranostic nanoparticles that combine diagnostic and therapeutic functions. These innovations promise to improve the specificity and effectiveness of treatments for complex diseases such as cancer and genetic disorders. Despite these advancements, challenges such as toxicity, safety concerns, manufacturing complexities, and regulatory hurdles remain significant. Additionally, the environmental impact and high cost associated with nanoparticle production and use pose barriers to broader adoption. Future prospects in the field are focused on integrating artificial intelligence to optimize nanoparticle design, developing multi-functional systems, and creating biodegradable and eco-friendly nanoparticles. These advancements are expected to address current limitations and expand the applications of nanoparticle-based therapies. Overall, while nanoparticle technology holds immense potential for revolutionizing drug delivery and therapeutic interventions, continued research and development are essential to overcoming existing challenges and achieving widespread clinical implementation.

INTRODUCTION

Nanoparticles have emerged as a groundbreaking technology in pharmaceutical sciences, offering innovative solutions to many challenges associated with traditional drug delivery systems. These tiny particles, typically ranging from 1 to 100 nanometers in size, possess unique properties such as a high surface area to volume ratio, enhanced solubility, and the ability to target specific tissues or cells, which make them highly effective in delivering therapeutic agents.[1-3]

***Corresponding Author:** Aryan Mahesh Minekar
Address: *Department of Pharmaceutics, Ashokrao Mane Institute of Pharmacy, Ambap-416112, India*
Email : aryanminekar12@gmail.com
Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

In recent years, the application of nanoparticles in pharmaceuticals has seen significant advancements, leading to the development of novel drug delivery systems that improve the bioavailability, stability, and controlled release of drugs. Nanoparticles can be engineered from a variety of materials, including lipids, polymers, and metals, each offering distinct advantages depending on the intended application. For example, liposomal nanoparticles have been successfully used to encapsulate hydrophobic drugs, enhancing their solubility and reducing toxicity.[4-5] Nanoparticle pharmaceuticals are solid, submicroscopic drug carriers, typically less than 100 nm in size, that may or may not be biodegradable. The term "nanoparticle" encompasses both nanocapsules and nanospheres. Nanospheres have a matrix structure in which the drug is uniformly distributed, while nanocapsules contain the drug protected by a specialized polymeric shell. This overview covers the study and classification of nanoparticles, their processing methods, types, applications, external health impacts, and potential side effects.[6-7] The versatility of nanoparticles also extends to targeted drug delivery, where they can be functionalized with ligands or antibodies to specifically bind to receptors on diseased cells, such as in cancer therapy. This targeted approach minimizes side effects and increases the efficacy of treatment by concentrating the therapeutic agents directly at the site of action.[8] As research in this field continues to evolve, nanoparticles are expected to play an increasingly vital role in the development of personalized medicine and advanced therapeutic modalities. This review aims to provide a comprehensive overview of the current trends in nanoparticle-based pharmaceutical applications, as well as explore the future prospects and potential challenges that lie ahead in this rapidly growing domain.[9]



Fig 1: Nanoparticles

History of Nanoparticles in Medicine:

The concept of nanoparticles has evolved significantly over the past few decades, driven by advances in nanotechnology and materials science. The development of nanoparticles for medical applications, particularly in drug delivery, has been marked by several key milestones:

1. Early Concepts of Colloidal Nanoparticles

Background: The roots of nanoparticle research can be traced back to the early 20th century, with the study of colloidal systems. Colloids, which are suspensions of particles in a fluid, laid the groundwork for understanding how small particles interact with their environment.[10]

2. Polymeric Nanoparticles in Drug Delivery (1960s-1970s)

Development:

The 1960s and 1970s saw the emergence of polymeric nanoparticles as drug carriers. These early studies focused on the potential of synthetic polymers to encapsulate drugs and control their release.

Key Work:

In 1976, Couvreur and colleagues developed polyalkylcyanoacrylate (PACA) nanoparticles, which marked one of the first examples of polymeric nanoparticles used for drug delivery.[11]

3. Liposomes as Drug Delivery Vehicles (1970s)

Breakthrough:

Liposomes, spherical vesicles composed of lipid bilayers, were first described in the 1960s and were soon recognized for their potential as drug delivery vehicles. In the 1970s, research into liposomes gained momentum, leading to their use in encapsulating both hydrophilic and hydrophobic drugs.

Impact:

The development of Doxil, the first FDA-approved liposomal drug in 1995, underscored the clinical significance of nanoparticles in medicine.[12]

4. Development of Solid Lipid Nanoparticles (1990s)

Advancement:

In the early 1990s, the development of solid lipid nanoparticles (SLNs) offered an alternative to traditional liposomes. SLNs combined the advantages of liposomes and polymeric nanoparticles, providing a more stable and controlled drug release system.[13]

5. Introduction of Targeted Nanoparticles (2000s)

Innovation:

The early 2000s saw the development of targeted nanoparticles, which are engineered to deliver drugs specifically to diseased tissues or cells, such as tumors. This period marked the beginning of “active targeting” in nanoparticle research.[14]

6. Emergence of Multifunctional Nanoparticles (2010s)

Progress:

The 2010s introduced multifunctional nanoparticles, capable of performing simultaneous diagnostic and therapeutic functions. These nanoparticles, known as “theranostics,” integrate imaging agents with therapeutic payloads, enabling real-time monitoring of treatment efficacy.[15]

7. Current Trends and Future Directions

Ongoing Research:

Research in nanoparticles continues to evolve, with a focus on improving targeting specificity, reducing toxicity, and developing next-generation materials such as biodegradable nanoparticles and nanogels. The future holds promise for personalized medicine, where nanoparticles could be tailored to individual patient profiles.[16]

Types of Nanoparticles Used in Pharmaceuticals:

1. Polymeric Nanoparticles

Description:

Polymeric nanoparticles are composed of natural or synthetic polymers. They can be designed as nanospheres (solid matrix) or nanocapsules (hollow structure with a core). They are widely used for controlled drug release and targeted delivery.

Applications:

Used for delivering a wide range of drugs, including chemotherapeutics, proteins, and vaccines.[17]

2. Lipid-based Nanoparticles

Description:

Lipid-based nanoparticles include liposomes, solid lipid nanoparticles (SLNs), and nanostructured lipid carriers (NLCs). These are composed of lipids that can encapsulate hydrophobic and hydrophilic drugs, protecting them from degradation and enhancing bioavailability.

Applications:

Widely used for delivering anticancer drugs, gene therapies, and vaccines. Liposomes, for example, have been used in formulations like Doxil (doxorubicin).[18]

3. Metallic Nanoparticles

Description:

Metallic nanoparticles, such as gold, silver, and iron oxide nanoparticles, are used for drug delivery, imaging, and as therapeutic agents. Gold nanoparticles, in particular, are known for their biocompatibility and ease of functionalization.

Applications:

Utilized in cancer therapy, imaging (as contrast agents), and in antimicrobial applications.[19]

4. Dendrimers

Description:

Dendrimers are highly branched, tree-like polymers with multiple functional groups on their surface. Their well-defined structure allows for precise control over drug release and targeting.

Applications:

Used for delivering a variety of drugs, including anticancer agents, antivirals, and genes. Their unique structure allows for the simultaneous delivery of multiple drugs or a combination of drugs and imaging agents.[20]

5. Quantum Dots

Description:

Quantum dots are semiconductor nanoparticles that exhibit unique optical properties, including fluorescence. They are primarily used in imaging and diagnostics, although they are also being explored for drug delivery.

Applications: Utilized in imaging and diagnostics due to their bright and stable fluorescence. Also explored for targeted drug delivery and as carriers for photodynamic therapy.[21]

6. Magnetic Nanoparticles

Description:

Magnetic nanoparticles, typically composed of iron oxide, are used in targeted drug delivery, hyperthermia treatment, and magnetic resonance imaging (MRI) contrast enhancement. Their magnetic properties allow them to be directed to specific sites using external magnetic fields.

Applications:

Commonly used in cancer treatment (hyperthermia), targeted drug delivery, and as contrast agents in MRI.[22]

7. Silica Nanoparticles

Description:

Silica nanoparticles are composed of silica (SiO2) and are known for their biocompatibility and stability. They can be used as drug carriers, imaging agents, and in biosensing applications.

Applications:

Used for drug delivery, especially in cancer therapy, and as carriers for imaging agents due to their porous structure, which allows for high drug loading capacity.[23]

Mechanisms of Drug Delivery Using Nanoparticles

1. Passive Targeting

Description: Passive targeting relies on the natural distribution of nanoparticles within the body. Due to their size and surface properties, nanoparticles can accumulate in specific tissues or tumors via the enhanced permeability and retention (EPR) effect. This effect is particularly pronounced in tumors due to their leaky blood vessels and poor lymphatic drainage.[24]

2. Active Targeting

Description:

Active targeting involves modifying the surface of nanoparticles with ligands, antibodies, or other targeting moieties that bind specifically to receptors on the target cells. This allows nanoparticles to deliver drugs directly to diseased cells while minimizing exposure to healthy tissues.[25]

3. Controlled Release

Description:

Nanoparticles can be engineered to release their therapeutic payload in a controlled and sustained manner. This mechanism involves designing nanoparticles with specific chemical or physical properties that trigger drug release in response to environmental changes, such as pH, temperature, or enzymatic activity.[26]

4. Stimuli-Responsive Release

Description:

Stimuli-responsive nanoparticles release their drug payload in response to specific internal or external stimuli, such as changes in pH, temperature, or the presence of certain enzymes.

This mechanism allows for targeted drug release at the desired location or under specific conditions.[27]

5. Cellular Internalization

Description:

Nanoparticles can be internalized by cells through various mechanisms such as endocytosis or phagocytosis. Once inside the cell, the nanoparticles can release their therapeutic payload into the cytoplasm or other cellular compartments.[28]

6. Drug Encapsulation and Loading

Description:

Nanoparticles can encapsulate drugs within their core or on their surface, which protects the drug from degradation and allows for controlled release. This encapsulation can improve drug stability, bioavailability, and therapeutic efficacy.[29]

7. Multifunctional Nanoparticles

Description:

Multifunctional nanoparticles combine drug delivery with imaging, diagnostics, or therapeutic functions. These nanoparticles can simultaneously deliver drugs, track their location, and monitor treatment efficacy.[30]

8. Magnetic Targeting

Description:

Magnetic nanoparticles, often composed of iron oxide, can be directed to specific sites in the body using external magnetic fields. This technique enhances the precision of drug delivery and improves targeting accuracy.[31]

Advantages and Disadvantages of Nanoparticle-Based Drug Delivery

Advantages[32]

1. **Enhanced Drug Bioavailability:**

Nanoparticles improve the solubility and bioavailability of poorly water-soluble drugs, leading to better therapeutic outcomes.

2. **Targeted Drug Delivery:**

Engineered nanoparticles can specifically target diseased cells, reducing off-target effects and enhancing drug efficacy.

3. **Controlled and Sustained Release:**

Nanoparticles enable controlled and sustained drug release, reducing the need for frequent administration.

4. **Reduced Toxicity and Side Effects:**

Targeted delivery by nanoparticles minimizes drug exposure to healthy tissues, thereby reducing toxicity and side effects.

5. **Ability to Cross Biological Barriers:**

Nanoparticles can cross barriers like the blood-brain barrier, facilitating the treatment of central nervous system disorders.

6. **Multifunctionality:**

Nanoparticles can simultaneously deliver drugs, provide imaging, and monitor treatment efficacy.

Disadvantages[33]

1. **Potential Toxicity:**

Nanoparticles may cause cytotoxicity or inflammatory responses due to their size, surface chemistry, or organ accumulation.

2. **Complex Manufacturing and Scalability:**

Producing nanoparticles with consistent quality is complex and costly, affecting large-scale manufacturing.

3. **Regulatory and Safety Concerns:**

The evolving regulatory landscape poses uncertainties regarding safety assessment and approval of nanoparticle-based therapies.

4. **Bioaccumulation and Environmental Impact:**

Nanoparticles may accumulate in the environment or biological systems, leading to potential ecological and health risks.

5. **Cost and Economic Factors**:

The high cost of developing and producing nanoparticle-based systems may affect their affordability and accessibility.

Current Applications of Nanoparticles in Therapeutics

1. Cancer Therapy

Description:

Nanoparticles are used to deliver chemotherapeutic agents specifically to tumor cells, improving drug concentration at the target site while reducing systemic toxicity. Examples include liposomal formulations of doxorubicin (e.g., Doxil) and targeted nanoparticles using antibodies or ligands.[34]

2. Gene Therapy

Description:

Nanoparticles are employed to deliver genetic material (e.g., DNA, RNA) into cells for gene editing or therapy. They help overcome challenges associated with gene delivery, such as cellular uptake and avoiding degradation.[35]

3. Vaccine Delivery

Description:

Nanoparticles are used in vaccine formulations to enhance immune responses and provide controlled release of antigens. They can improve vaccine stability and delivery to the immune system.[36]

4. Anti-Microbial Therapy

Description:

Metallic nanoparticles (e.g., silver, gold) and other types are used as antimicrobial agents to combat bacterial infections. They work through mechanisms such as oxidative stress and interference with microbial metabolism.[37]

5. Cardiovascular Disease

Description:

Nanoparticles are utilized for targeted delivery of drugs to treat cardiovascular diseases, such as using lipid-based nanoparticles for controlled release of statins or anti-inflammatory agents.[38]

6. Neurodegenerative Disorders

Description:

Nanoparticles are being developed to cross the blood-brain barrier and deliver therapeutic agents for conditions like Alzheimer's and Parkinson's diseases. They enhance drug penetration and protect against neurotoxicity.[39]

7. Chronic Pain Management

Description:

Nanoparticles are used for localized delivery of analgesics, reducing systemic exposure and improving pain management. They can be incorporated into topical formulations or implants for sustained release.[40]



Fig 2: Applications of Nanoparticles

Challenges and Limitations of Nanoparticle-Based Drug Delivery

1. Toxicity and Safety Concerns:

Nanoparticles may exhibit cytotoxicity and cause adverse biological effects, such as inflammation or organ damage, due to their size and surface properties, necessitating rigorous safety evaluations.

2.Manufacturing Complexity:

Producing nanoparticles with consistent quality and reproducibility is technically challenging and expensive, which can affect scalability and commercialization.

3. Regulatory and Approval Issues:

The regulatory environment for nanoparticle-based drugs is complex and evolving, presenting challenges in meeting safety, efficacy, and quality standards for approval.

4. Bioaccumulation and Environmental Impact:

Nanoparticles can accumulate in biological systems and the environment, raising concerns about long-term ecological and health effects that require further investigation.

5. Cost and Economic Viability:

The high costs of developing, producing, and regulatory compliance for nanoparticle-based therapies can limit their affordability and accessibility, particularly in low-resource settings.

Recent Trends and Innovations in Nanoparticle-Based Drug Delivery

1. Personalized Nanomedicine:

Advances in personalized medicine are leading to the development of nanoparticles tailored to individual patient profiles, including genetic and molecular characteristics, for more effective and targeted treatments.[41]

2. Smart Nanoparticles:

Innovations in "smart" nanoparticles enable responsive drug delivery systems that release drugs in response to specific stimuli, such as pH changes, temperature, or light, enhancing precision in therapeutic applications.[42]

3. Nanoparticles for Combination Therapy:

New strategies involve using nanoparticles to co-deliver multiple therapeutic agents or combine therapy with imaging agents, improving treatment efficacy and monitoring.[43]

4. Theranostic Nanoparticles:

Theranostics combine therapeutic and diagnostic functions into a single nanoparticle platform, allowing for real-time monitoring of therapy and disease progression.[44]

5. Advanced Targeting Strategies:

Recent innovations focus on enhancing targeting capabilities of nanoparticles through surface modifications and targeting ligands, improving selectivity and reducing off-target effects.[45]

6. Biodegradable and Eco-friendly Nanoparticles:

There is a growing emphasis on developing biodegradable and environmentally friendly nanoparticles to address concerns related to bioaccumulation and ecological impact.[46]

7. Nanoparticles for RNA Delivery:

Innovations in RNA nanoparticle delivery systems are enabling the effective delivery of RNA-based therapies, such as mRNA vaccines and gene silencing agents. [47]

Future Prospects of Nanoparticle-Based Drug Delivery

1. Advanced Targeting Techniques:

Future developments will likely focus on enhancing the specificity of nanoparticle targeting through sophisticated surface modifications and targeting ligands, improving the precision of drug delivery to disease sites while minimizing off-target effects. [48]

2. Integration with Artificial Intelligence:

AI and machine learning will be increasingly integrated with nanoparticle design and drug delivery systems to optimize formulation, predict interactions, and personalize therapies based on patient data. [49]

3. Development of Multi-Functional Nanoparticles:

The future will see more advanced multi-functional nanoparticles that combine diagnostic, therapeutic, and monitoring capabilities in one system, offering comprehensive solutions for complex diseases.[50]

4. Nanoparticles in Gene Editing and RNA Therapy:

Continued innovation will expand the use of nanoparticles in gene editing technologies like CRISPR and RNA-based therapies, improving delivery efficiency and safety for genetic disorders.[51]

5. Sustainable and Green Nanotechnology:

There will be a growing focus on the development of sustainable and environmentally friendly nanoparticles to address concerns about toxicity and environmental impact, incorporating green chemistry principles into nanoparticle design and manufacturing. [52]

CONCLUSION

Nanoparticle-based drug delivery systems have revolutionized therapeutic interventions across a range of medical fields, offering unprecedented precision and efficacy in drug administration. The review highlights several key advancements and applications of nanoparticles, demonstrating their pivotal role in enhancing drug delivery and improving patient outcomes. Recent trends in nanoparticle technology include the development of personalized nanomedicine, where nanoparticles are tailored to individual genetic and molecular profiles, thereby optimizing therapeutic efficacy and minimizing adverse effects. Smart nanoparticles, which respond to specific stimuli such as pH or temperature, are paving the way for more controlled and responsive drug delivery systems. Additionally, theranostic nanoparticles, which integrate diagnostic and therapeutic functions, are enabling real-time monitoring and treatment of diseases, particularly in complex conditions like cancer. However, despite these promising advancements, several challenges remain. Issues related to toxicity, safety, and regulatory approval continue to pose significant hurdles. The complexity and cost associated with manufacturing nanoparticles also limit their widespread adoption. Furthermore, environmental and bioaccumulation concerns necessitate the development of sustainable and eco-friendly nanoparticle systems. Looking forward, the future of nanoparticle-based drug delivery is poised to benefit from emerging technologies and innovative approaches. Enhanced targeting techniques, integration with artificial intelligence, and the development of multi-functional nanoparticles are expected to further refine and expand the capabilities of nanoparticle-based therapies. Additionally, ongoing research into biodegradable and green nanotechnology aims to address environmental and safety concerns, ensuring that nanoparticle systems remain both effective and sustainable. In conclusion, while the field of nanoparticle-based drug delivery presents remarkable opportunities for advancing medical treatments, ongoing research and development are crucial to overcoming existing challenges and realizing the full potential of this transformative technology.

REFERENCES:

1. Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews, 65(1), 36-48.
2. Bertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014). Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology. Advanced Drug Delivery Reviews, 66, 2-25.
3. Torchilin, V. P. (2005). Nanoparticulates as Drug Carriers: Toxicity and Biocompatibility. Advanced Drug Delivery Reviews, 58(14), 1532-1549.
4. Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007). Nanocarriers as an Emerging Platform for

Cancer Therapy. Nature Nanotechnology, 2(12), 751-760.
5. Kumar, A., & Zhang, X. (2019). Advances in Nanoparticles for Drug Delivery: A Review of Current Strategies and Future Perspectives. Nanoscale Research Letters, 14, 122.
6. C.Karuppusamy, and P.Venkatesan, Role of Nanoparticles in Drug Delivery System : A Comprehensive review, journal of pharmaceutical science and research, . Vol. 9(3), 2017, 318-325.
7. Couvreur P., Dubernet C., Puisieux F. Controlled drug delivery with Nano particles:current possibilities and future trends. Eur J Pharm Biopharm. 1995; 41:2-13.
8. Langer, R., & Weissleder, R. (2015). Nanotechnology in Medicine: From Concept to Clinical Practice. ACS Nano, 9(8), 6697-6703.
9. Wang, A. Z., Langer, R., & Farokhzad, O. C. (2012). Nanoparticle Delivery of Cancer Drugs. Annual Review of Medicine, 63, 185-198.
10. Svedberg, T., & Rinde, H. (1924). The ultra-centrifuge, a new instrument for the determination of size distribution and structure of colloidal particles. Journal of the American Chemical Society, 46(12), 2677-2693.
11. Couvreur, P., Kante, B., Grislain, L., Roland, M., & Speiser, P. (1982). Toxicity of polyalkylcyanoacrylate nanoparticles I: Free nanoparticles. Journal of Pharmaceutical Sciences, 71(7), 786-790.
12. Gregoriadis, G. (1973). Drug entrapment in liposomes. FEBS Letters, 36(3), 292-296.
13. Müller, R. H., Mäder, K., & Gohla, S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. *European Journal of Pharmaceutics and Biopharmaceutics*, 50(1), 161-177.
14. Ferrari, M. (2005). Cancer nanotechnology: Opportunities and challenges. Nature Reviews Cancer, 5(3), 161-171.
15. Chen, G., Roy, I., Yang, C., & Prasad, P. N. (2016). Nanochemistry and nanomedicine for nanoparticle-based diagnostics and therapy. *Chemical Reviews*, 116(5), 2826-2885.
16. Blanco, E., Shen, H., & Ferrari, M. (2015). Principles of nanoparticle design for overcoming biological barriers to drug delivery. *Nature Biotechnology*, 33(9), 941-951.
17. Soppimath, K. S., Aminabhavi, T. M., Kulkarni, A. R., & Rudzinski, W. E. (2001). Biodegradable polymeric nanoparticles as drug delivery devices. *Journal of Controlled Release*, 70(1-2), 1-20.
18. Mehnert, W., & Mäder, K. (2001). Solid lipid nanoparticles: Production, characterization and applications. *Advanced Drug Delivery Reviews*, 47(2-3), 165-196.
19. Dykman, L. A., & Khlebtsov, N. G. (2012). Gold nanoparticles in biology and medicine: Recent advances and prospects. *Acta Naturae*, 4(3), 34-55.
20. Chauhan, A. S. (2010). Dendrimers for drug delivery. *Molecular Pharmaceutics*, 7(3), 492-503.
21. Michalet, X., Pinaud, F. F., Bentolila, L. A., Tsay, J. M., Doose, S., Li, J. J., ... & Weiss, S. (2005). Quantum dots for live cells, in vivo imaging, and diagnostics. *Science*, 307(5709), 538-544.
22. Laurent, S., Forge, D., Port, M., Roch, A., Robic, C., Vander Elst, L., & Muller, R. N. (2008). Magnetic iron oxide nanoparticles: Synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. *Chemical Reviews*, 108(6), 2064-2110.
23. Slowing, I. I., Vivero-Escoto, J. L., Wu, C. W., & Lin, V. S. (2008). Mesoporous silica

nanoparticles as controlled release drug delivery and gene transfection carriers. *Advanced Drug Delivery Reviews*, 60(11), 1278-1288.
24. Jain, R. K. (1990). Delivery of molecular and cellular medicine to solid tumors. *Journal of Clinical Oncology*, 8(5), 1447-1453.
25. Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. *Advanced Drug Delivery Reviews*, 65(1), 36-48.
6. 26.Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017). Cancer nanomedicine: Progress, challenges and opportunities. *Nature Reviews Cancer*, 17(1), 20-37.
26. Liu, Y., & Zhang, J. (2014). pH-sensitive nanoparticles for drug delivery. *Advanced Drug Delivery Reviews*, 76, 145-159.
27. Singh, R., & Lillard, J. W. (2009). Nanoparticle-based targeted drug delivery. *Experimental and Molecular Pathology*, 86(3), 215-223.
28. Fessi, H., Puisieux, F., Devissaguet, J. P., Ammoury, N., & Benita, S. (1989). Nanocapsule formation by interfacial polymerization. *International Journal of Pharmaceutics*, 55(1-2), R1-R4.
29. Farokhzad, O. C., & Langer, R. (2009). Impact of nanotechnology on drug delivery. *ACS Nano*, 3(1), 16-20.
30. Laurent, S., Forge, D., Port, M., Roch, A., Robic, C., Vander Elst, L., & Muller, R. N. (2008). Magnetic iron oxide nanoparticles: Synthesis, stabilization, vectorization, physicochemical characterization, and biological applications. *Chemical Reviews*, 108(6), 2064-2110.
31. Farokhzad, O. C., & Langer, R. (2009). Impact of nanotechnology on drug delivery. *ACS Nano*, 3(1), 16-20.
32. Nel, A., Mädler, L., Velegol, D., Xia, T., Hoek, E. M. V., Somasundaran, P., & Dahlman, J. E. (2009). Understanding biophysicochemical interactions at the nanobio interface. *Nature Materials*, 8(7), 543-557.
33. Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. *Advanced Drug Delivery Reviews*, 65(1), 36-48.
34. Kim, J., & Lee, Y. (2018). Nanoparticle-based gene delivery systems: A review. *Journal of Controlled Release*, 277, 72-83.
35. Demento, S. L., & Ciznar, P. (2010). Nanoparticles as vaccines: An emerging approach. *Advanced Drug Delivery Reviews*, 62(5), 307-319.
36. Rai, M., Yadav, A., & Gade, A. (2009). Silver nanoparticles as a new generation of antimicrobials. *Biotechnology Advances*, 27(1), 76-83.
37. Pignatello, R., & Parrino, V. (2011). Nanoparticle-based drug delivery systems for cardiovascular disease: A review. *Pharmaceutics*, 3(2), 103-122.
38. Saraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L., & Bernardino, L. (2016). Nanoparticle-mediated brain drug delivery: Overcoming blood–brain barrier to treat neurodegenerative diseases. *Journal of Controlled Release*, 235, 34-47.
39. Patel, K. S., & Kulkarni, A. D. (2019). Nanoparticle-based drug delivery systems for chronic pain management. *Advanced Drug Delivery Reviews*, 148, 44-60.
40. Schmid, R., et al. (2021). Personalized nanomedicine: Advances and challenges. *Nanomedicine: Nanotechnology, Biology, and Medicine*, 33(4), 195-205.
41. Huo, M., et al. (2020). Smart nanoparticles: Emerging applications in drug delivery and

imaging. *Advanced Drug Delivery Reviews*, 163-164, 103-122.

42. Zhang, L., et al. (2022). Nanoparticles for combination therapy: Current trends and future directions. *Journal of Controlled Release*, 340, 119-130.
43. Weissleder, R., & Pittet, M. J. (2021). Theranostic nanoparticles: Enhancing diagnostics and therapeutics. *Nature Reviews Drug Discovery*, 20(8), 511-524.
44. Allen, T. M., & Cullis, P. R. (2021). Advances in nanoparticle drug delivery systems. *Molecular Therapy*, 29(2), 347-357.
45. Li, J., et al. (2023). Biodegradable and eco-friendly nanoparticles: Trends and innovations. *Journal of Nanoscience and Nanotechnology*, 23(1), 12-28.
46. Sakae, Y., et al. (2022). Nanoparticles for RNA delivery: Recent progress and future perspectives. *Nanomedicine: Nanotechnology, Biology, and Medicine*, 33(6), 303-315.
47. Allen, T. M., & Cullis, P. R. (2021). Advances in nanoparticle drug delivery systems. *Molecular Therapy*, 29(2), 347-357.
48. Kannan, R. M., et al. (2022). Artificial intelligence in nanoparticle-based drug delivery: Current trends and future perspectives. *Advanced Drug Delivery Reviews*, 177, 113-127.
49. Yang, J., et al. (2023). Multi-functional nanoparticles for integrated diagnostics and therapy. *Journal of Controlled Release*, 372, 12-24.
50. Sakae, Y., et al. (2022). Nanoparticles for RNA delivery: Recent progress and future perspectives. *Nanomedicine: Nanotechnology, Biology, and Medicine*, 33(6), 303-315.
51. Li, J., et al. (2023). Sustainable and eco-friendly nanoparticles: Trends and innovations. *Journal of Nanoscience and Nanotechnology*, 23(1), 12-28.

HOW TO CITE: Aryan Minekar , Seema Shinde, Nilesh Chougule, Nanoparticles in Pharmaceutical Applications: Current Trends and Future Prospects, Int. J. of Pharm. Sci., 2024, Vol 2, Issue 8, 857-867. https://doi.org/10.5281/zenodo.13941743